No survival advantage to adding atezolizumab to bevacizumab in ovarian cancer

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 17 / Springer Healthcare

No survival advantage to adding atezolizumab to bevacizumab in ovarian cancer

Oncology Ovarian Cancer ESMO-2021

Description

Mansoor Raza Mirza gives his thoughts on the EORTC-1508 trial, which explored the addition of atezolizumab to bevacizumab for the treatment of platinum-resistant ovarian cancer, and the need for more drug combination studies

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.